Research
Metabolic adaptation
Durable LVAD patients treated with GLP-1 RA had a significant weight reduction from 116 kg to 110 kg (p-value < 0.001).
GLP-1 RA may be effective for weight management in LVAD patients.
StrongSupportsmedium confidence
At 1 year follow-up, the patient's weight was significantly reduced (116 (98-134) vs. 110 (91-129) kg, p-value < 0.001).
Why this rating
Based on a retrospective analysis of patient outcomes.
Source
Glucagon‐Like Peptide‐1 Receptor Agonists in Patients With Durable Left Ventricular Assist Devices
B. Elad et al. · Artificial Organs · 2025
cohort · n=40Cited 4×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →